Quick Answer
InMed Pharmaceuticals Inc. reported Stockholders Equity of $13.43 million for the year ending 2025.
- InMed Pharmaceuticals Inc. showed an increase of +45.9% in Stockholders Equity from 2024 to 2025.
- This data is from InMed Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $11.47 million | Q4 2019: $9.61 million | Q1 2020: $7.07 million | Q3 2020: $4.49 million | Q4 2020: $7.59 million | Q1 2021: $10.41 million | Q3 2021: $15.22 million | Q4 2021: $14.17 million | Q1 2022: $10.89 million | Q3 2022: $11.01 million | Q4 2022: $14.34 million | Q1 2023: $12.39 million | Q3 2023: -$9.58 million | Q4 2023: $12.77 million | Q1 2024: $11.10 million | Q2 2024: $9.21 million | Q3 2024: $8.40 million | Q4 2024: $6.18 million | Q1 2025: $7.02 million | Q2 2025: $13.43 million | Q3 2025: $11.59 million | Q4 2025: $9.59 million.
- Over the full 7 years of available data (2019 to 2025), InMed Pharmaceuticals Inc.'s Stockholders Equity has declined by 5.7%.
- Historical annual values: Fiscal year 2025: $13.43 million | Fiscal year 2024: $9.21 million | Fiscal year 2023: $12.09 million | Fiscal year 2022: $9.08 million | Fiscal year 2021: $7.38 million | Fiscal year 2020: $5.88 million | Fiscal year 2019: $14.24 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: